Attention deficit hyperactivity disorder

Tuned Receives $3.5 Million in Funding to Shape the Future of Hearing Wellness

Retrieved on: 
Wednesday, February 8, 2023

Tuned , a digital hearing health company focused on providing hearing care for all, today announced that it raised $3.5 million in funding led by Distributed Ventures with participation from Idealab NY , and Elements Health Ventures .

Key Points: 
  • Tuned , a digital hearing health company focused on providing hearing care for all, today announced that it raised $3.5 million in funding led by Distributed Ventures with participation from Idealab NY , and Elements Health Ventures .
  • “Having been impacted by hearing loss myself, I’ve experienced firsthand how expensive and ineffective this vertical of healthcare can be and the need for a telehealth platform that makes hearing care more attainable.
  • “There is a huge misconception that hearing care is an elderly issue and that the only solution is hearing aids.
  • The Tuned 360 Hearing Profile is the most advanced hearing screening available online, offering an affordable, convenient, and accessible solution on a global scale.

Can ABA Therapy be used to treat ADHD at Westside Children's Therapy?

Retrieved on: 
Tuesday, February 7, 2023

But for parents of a child with Autism or ADHD, these struggles and challenges can be more pronounced.

Key Points: 
  • But for parents of a child with Autism or ADHD, these struggles and challenges can be more pronounced.
  • Yet, Westside Children's Therapy therapists know that Autism and ADHD often go together, with up to 50% of children with Autism also meeting the criteria for ADHD.
  • From a behavior therapy standpoint at Westside Children's Therapy, the "why" does matter.
  • To learn more about if ABA Therapy can help treat ADHD, check out this blog .

HMP Global names Dr. Craig Chepke as Scientific Advisor for Psych Congress Educational Programs

Retrieved on: 
Thursday, January 26, 2023

MALVERN, Pa., Jan. 26, 2023 /PRNewswire-PRWeb/ -- HMP Global, the leading omnichannel healthcare company, today announced that Psych Congress Steering Committee member Dr. Craig Chepke has been named Scientific Advisor for the entire Psych Congress portfolio, including Psych Congress, the nation's largest independent mental health educational conference on practical psychopharmacology, Psych Congress Elevate, Psych Congress Regionals, and the newly announced Psych Congress NP Institute In-Person event.

Key Points: 
  • MALVERN, Pa., Jan. 26, 2023 /PRNewswire-PRWeb/ -- HMP Global, the leading omnichannel healthcare company, today announced that Psych Congress Steering Committee member Dr. Craig Chepke has been named Scientific Advisor for the entire Psych Congress portfolio, including Psych Congress , the nation's largest independent mental health educational conference on practical psychopharmacology, Psych Congress Elevate , Psych Congress Regionals , and the newly announced Psych Congress NP Institute In-Person event.
  • As Scientific Advisor, Dr. Chepke will work closely with the steering committees and faculty of Psych Congress events and programs to develop high-quality practical and advanced evidence-based educational content relevant to all mental health team members.
  • "I've heard Dr. Chepke described as a rising star, but I disagree," said Rakesh Jain, MD, MPH, Psych Congress Co-Chair and Clinical Professor of Psychiatry at Texas Tech University School of Medicine.
  • For more information or to register for this and other upcoming Psych Congress events, visit psychcongress.com .

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Retrieved on: 
Thursday, January 19, 2023

FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the Phase IIa study of its medical treatment, ABV-1505 ADHD, on January 14, 2023 at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session.

Key Points: 
  • FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the Phase IIa study of its medical treatment, ABV-1505 ADHD, on January 14, 2023 at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session.
  • APSARD is a world-renowned organization consisting of a broad spectrum of allied mental health experts working to improve the quality of care for patients with ADHD through the advancement and dissemination of research, and evidence-based practices.
  • The active pharmaceutical ingredient of ABV-1505, PDC-1421, was used in the Phase IIa study which involved six adult subjects with confirmed ADHD.
  • “We were pleased to have the impressive ABV-1505 ADHD Phase IIa study results presented by Dr. McBurnett at the 2023 APSARD Conference,” said Dr. Howard Doong, Chief Executive Officer of the Company.

XGC Software Inc. Announces Execution of a Non-Binding Letter of Intent to Acquire IntelliGym Labs, an Israeli-Based Leader in Cognitive Enhancement

Retrieved on: 
Thursday, January 5, 2023

This technology platform has been repurposed for cognitive training and enhancement for athletes.

Key Points: 
  • This technology platform has been repurposed for cognitive training and enhancement for athletes.
  • The players then trains their decision-making capabilities, awareness, and anticipation, making meaningful choices with respect to game-time performance.
  • IntelliGym has spent years working with the scientific community testing and researching the benefits of its cognitive training software with a major focus on players’ performance and safety.
  • IntelliGym intends to expand into other sports verticals as well as other verticals that would benefit from IntelliGym’s patented cognitive enhancement technology.

Global Attention Deficit Hyperactivity Disorder Market Report 2022: Increasing Recognition of Behavioral Therapy Benefits Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023

Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.

Key Points: 
  • Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.
  • The stimulants segment procured the highest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • The retail pharmacy segment recorded the largest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • On the basis of region, the attention deficit hyperactivity disorder market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Hyundai-Kia Reveals Details of ZER01NE Creative Platform Promoting Pioneering Startups at CES 2023

Retrieved on: 
Wednesday, January 4, 2023

The ZER01NE Platform highlights Hyundai Motor Group's strategy of building relationships with and nurturing an ecosystem for creators and startups.

Key Points: 
  • The ZER01NE Platform highlights Hyundai Motor Group's strategy of building relationships with and nurturing an ecosystem for creators and startups.
  • "The ZER01NE initiative enables the Group to engage with the best and brightest next-generation startups to develop innovative solutions.
  • The five startups under the ZER01NE Company Builder program exhibiting at the ZER01NE pavilion at CES 2023 are VODA AI, Difon, Fittrix, Wondermove and AutoL.
  • This approach is typified by the latest 10 startups promoted through the ZER01NE Creative Platform at CES 2023 and the pioneering solutions they are developing.

Affinity Foundation Announces New Multi-Year Grant Partners, Committing $360,000 Over the Next Three Years

Retrieved on: 
Wednesday, December 14, 2022

The Affinity Foundation and its Board of Trustees are pleased to announce the launch of the Foundations new multi-year grant program.

Key Points: 
  • The Affinity Foundation and its Board of Trustees are pleased to announce the launch of the Foundations new multi-year grant program.
  • We are extremely proud to launch this program, said Karla Wallack, Executive Director of the Affinity Foundation.
  • Multi-year grants provide reliable grant revenue that leads to transformational results, and yet they are incredibly hard to find.
  • The Affinity Foundation is a registered nonprofit organization, you can further our mission by donating today (EIN #20-2706810).

ZER01NE, Hyundai-Kia's Creative Talent Platform, to Showcase Innovative Startups at CES 2023

Retrieved on: 
Thursday, December 15, 2022

At CES 2023, ZER01NE will showcase Hyundai Motor Group's strategy of engaging with and promoting global next-generation startups in the pursuit of innovative solutions to benefit humanity.

Key Points: 
  • At CES 2023, ZER01NE will showcase Hyundai Motor Group's strategy of engaging with and promoting global next-generation startups in the pursuit of innovative solutions to benefit humanity.
  • The ZER01NE Company Builder has fostered 76 in-house startups to date, of which 25 have succeeded in achieving spin-off status.
  • 10 startups will exhibit within the ZER01NE Pavilion at CES 2023, five under the patronage of the ZER01NE Accelerator and five under the banner of the ZER01NE Company Builder.
  • ZER01NE is a Creative Talent Platform that drives open innovation and creates an ecosystem for various creative talents such as artists, architects, designers, engineers, scientists, and entrepreneurs.

Applied Behavior Analysis in Orlando and Winter Garden, Florida Market Report 2022: Global Autism Spectrum Disorder Treatment Market is Expected to Reach $3.17 Billion by 2029

Retrieved on: 
Tuesday, December 6, 2022

DUBLIN, Dec. 6, 2022 /PRNewswire/ --The "Applied Behavior Analysis in Orlando and Winter Garden, Florida - Market Research Report 2022 " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 6, 2022 /PRNewswire/ --The "Applied Behavior Analysis in Orlando and Winter Garden, Florida - Market Research Report 2022 " report has been added to ResearchAndMarkets.com's offering.
  • The Applied Behavior Analysis (ABA) industry is rapidly changing.
  • New opportunities in the form of increased insurance coverage mandates, enhanced technology, and private equity investment place ABA practices in a unique position to capture additional growth.
  • There are 3.5 million children and adults with autism in America.